Pfizer’s Antithrombotic Fragmin Recommended For Use In Cancer Patients
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA's Oncologic Drugs Advisory Committee unanimously recommended approval of an sNDA for Pfizer's low molecular weight heparin Fragmin for treatment and prevention of venous thromboembolism in cancer patients
You may also be interested in...
Fragmin Clears FDA For VTE In Cancer Patients
FDA clears Pfizer/Eisai’s low molecular weight heparin following oncology panel’s unanimous recommendation for approval.
Fragmin Clears FDA For VTE In Cancer Patients
FDA clears Pfizer/Eisai’s low molecular weight heparin following oncology panel’s unanimous recommendation for approval.
Eisai Eyes Oncology Franchise With Acquisition Of Ligand Products
Company may also hire Ligand personnel in addition to purchase of Ontak, Targretin and Panretin.